Clinical Trial Update: Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating consolidation with nivolumab plus brentuximab vedotin after autologous stem cell transplant in high-risk classical Hodgkin lymphoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• OPDIVO (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-23